financetom
Business
financetom
/
Business
/
J.C. Flowers-backed Jefferson Capital eyes $1.1 billion valuation in US IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
J.C. Flowers-backed Jefferson Capital eyes $1.1 billion valuation in US IPO
Jun 13, 2025 5:13 AM

(Reuters) -Private equity-backed Jefferson Capital said on Friday it was targeting a valuation of up to $1.1 billion in its U.S. initial public offering, as buyout firms look to take advantage of an improving new listings market.

The company and some of its investors are seeking to raise up to $170 million by offering 10 million shares priced between $15 and $17 each, in what would be a rare flotation from the debt buyer industry.

Mounting pressure on financial sponsors to return money to investors is encouraging buyout firms to list their portfolio companies. A winning streak for latest U.S. stock market entrants has also boosted the IPO market, particularly for tariff-insulated companies.

Jefferson is offering 625,000 shares in the IPO, while selling stockholders, including J.C. Flowers, are putting up about 9.4 million shares.

Founded in 2002, the Minneapolis, Minnesota-based company purchases and manages charged-off and bankruptcy receivables with operations mainly in the U.S., Canada, the UK and Latin America.

It expanded into Canada with the acquisition of debt buyer Canaccede Financial Group in 2020.

The company had net income of $128.9 million and revenue of $433.3 million in 2024, up 15.6% and 34.1%, respectively, over the year earlier.

Jefferson competes against PRA Group, Encore Capital Group, Resurgent Capital Services and Cavalry Portfolio Services in its core U.S. market.

Investment firm J.C. Flowers had acquired Jefferson from buyout firm Flexpoint Ford in 2018.

Jefferson will list on the Nasdaq under the symbol "JCAP". Jefferies and Keefe, Bruyette & Woods are the lead underwriters for the offering.

J.C. Flowers will own about 68.9% of Jefferson after the offering.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blue Owl Capital Partners With Chirisa Technology Parks, PowerHouse to Develop Data Centers
Blue Owl Capital Partners With Chirisa Technology Parks, PowerHouse to Develop Data Centers
Aug 29, 2024
07:52 AM EDT, 08/29/2024 (MT Newswires) -- Blue Owl Capital (OWL) said Thursday that it has entered into a joint venture agreement with Chirisa Technology Parks and PowerHouse Data Centers to develop large-scale AI/HPC data centers. The joint venture will have up to $5 billion of capital for the development and deployment of new AI/HPC capacity across the US, the...
--iLearningEngines Shares Fall After Hindenburg Issues Short Report
--iLearningEngines Shares Fall After Hindenburg Issues Short Report
Aug 29, 2024
07:28 AM EDT, 08/29/2024 (MT Newswires) -- Price: 1.9600, Change: -1.23, Percent Change: -38.56 ...
iLearningEngines Shares Fall After Allegations by Short-Seller
iLearningEngines Shares Fall After Allegations by Short-Seller
Aug 29, 2024
07:58 AM EDT, 08/29/2024 (MT Newswires) -- iLearningEngines (AILE) shares were down more than 40% in Thursday's premarket activity after a short-selling blog critiqued its business model and revenue claims. Hindenburg Research said the AI-powered education company was borderline insolvent when it went public via a business combination deal in April. We suspect both the company's revenue and expenses are...
Merck scraps two late-stage trials of cancer drug Keytruda
Merck scraps two late-stage trials of cancer drug Keytruda
Aug 29, 2024
Aug 29 (Reuters) - Merck ( MRK ) has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial failures for the blockbuster drug. The company has been seeking to test Keytruda in combination with other treatments and expand its use in types...
Copyright 2023-2026 - www.financetom.com All Rights Reserved